Clinical Trial Update: EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating empagliflozin for heart failure with preserved ejection fraction in patients with end-stage renal disease on dialysis is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis | Phase 4 | Status: RECRUITING